• Home
  • Editorial Board
  • Articles
    • Editorials
    • Guest Articles
  • News
    • Featured
    • Biotech News
  • Interviews
    • Interviews – Academia
    • Interviews – Industry
  • Issues – Archives
  • Subscribe
  • Contact
Facebook Twitter Instagram
Trending
  • CDC Boss kicked out in RFK Jr.’s War on Corruption in pharma and healthcare
  • Prof. Rajeev Varshney FRS, now joins Australian Academy of Science
  • Dr. Cyrus S. Poonawalla, SII unveiled the newly built School for Hearing Impaired in Pune
  • AdFalciVax: ICMR’s New Malaria Vaccine: Hope or Premature Hype?”
  • The Sudden Deaths and COVID Vaccines: A Critical Analysis of the ICMR and AIIMS Studies
  • KGMU Scandal: Dr. Tulika Chandra Exposed in Crore Rupee Forgery and Scam
  • Zydus to launch market-specific dosage variants of Semaglutide, MD says
  • Biocon Biologics Launches Nepexto, Etanercept Biosimilar in Australia
Wednesday, October 1
Facebook Twitter Instagram LinkedIn
Biotech Express
  • Home
  • Editorial Board
  • Articles
    • Editorials
    • Guest Articles
  • News
    • Featured
    • Biotech News
  • Interviews
    1. Interviews – Academia
    2. Interviews – Industry
    Featured
    04/01/20241

    Interview: Reach to common man is the heart and soul of India International Science Festival- Dr. Arvind C Ranade Chief Coordinator, IISF- 2023

    Recent
    04/01/2024

    Interview: Reach to common man is the heart and soul of India International Science Festival- Dr. Arvind C Ranade Chief Coordinator, IISF- 2023

    22/05/2023

    Prof Rajeev Varshney becomes the 4th Indian Agricultural Scientist to be elected as Fellow of the Royal Society

    26/07/2022

    We are making best hygiene solutions through Biotech applications: Dr Rachna Dave, founder MicroGO

  • Issues – Archives
  • Subscribe
  • Contact
Biotech Express
You are at:Home»Biotech News»Bharat’s Intranasal Vaccine Speeds into Phase II on Heels of Strong Data

Bharat’s Intranasal Vaccine Speeds into Phase II on Heels of Strong Data

0
By Biotech Express on 10/09/2021 Biotech News, Featured, News-Research, SARS- CoV2 & COVID-19 Updates

Bharat Biotech’s intranasal COVID-19 vaccine candidate is expected to enter the Phase II portion of a Phase II/III study within the next few weeks. This marks the second vaccine against the novel coronavirus developed by the India-based company.

It’s a significant milestone for intranasal formulations. The nod from India’s Health Authority makes Bharat’s BBV154 candidate the first intranasal vaccine in development for COVID-19 in the country.

Phase I data from the intranasal formulation, is promising. Not only was the vaccine candidate well-tolerated, but the medication also blocks viral entry into the body. Full details of the study will be presented at a later date.

The company has suggested that an intranasal formulation of the vaccine provides a broad immune response at the site of infection, the mucus membranes of the nasal passages.

There is a school of thought that this type of administration will provide a stronger immune response than intramuscular injections currently used in multiple vaccines, including Bharat’s Covaxin, a whole virion inactivated COVID-19 vaccine, which has already been authorized in India. This is essential for blocking infection within an individual and the ability to transmit the virus.

The intranasal approach Bharat is taking with its second COVID-19 vaccine candidate is also one unsuccessfully attempted by Maryland-based Altimmune. In June, the company announced its intranasal vaccine candidate, dubbed AdCOVID, fell short in a Phase I study.

Share. Facebook Twitter Pinterest LinkedIn Tumblr Email
Biotech Express
  • Website
  • Facebook
  • Twitter
  • LinkedIn

ISSN: 2454-6968 | Biotech Express Magazine publishes articles in the field of biotechnology and allied sciences in a way that have never been presented earlier. It publishes Editorials, Guest Articles, Reports, Interviews, Current News of Govt. Academics and Business, Research Highlights and Notifications of Events, Jobs, Research Proposals in the field of Biotechnology, Biological Sciences, Life Sciences, Microbiology, Biochemistry, Neurosciences, Genetics, Medical Sciences, BioPharma etc.

Related Posts

AdFalciVax: ICMR’s New Malaria Vaccine: Hope or Premature Hype?”

KGMU Scandal: Dr. Tulika Chandra Exposed in Crore Rupee Forgery and Scam

Zydus to launch market-specific dosage variants of Semaglutide, MD says

Leave A Reply Cancel Reply

Current Issue – September 2025
Biotech Express – e-ISSN: 2454-6968

Editorial Board

For Authors – Article Submission and Guidelines

Peer Review Policies

License and Copyright

Advertisement

Recent Posts
  • CDC Boss kicked out in RFK Jr.’s War on Corruption in pharma and healthcare 21/09/2025
  • Prof. Rajeev Varshney FRS, now joins Australian Academy of Science 20/09/2025
  • Dr. Cyrus S. Poonawalla, SII unveiled the newly built School for Hearing Impaired in Pune 19/09/2025
  • AdFalciVax: ICMR’s New Malaria Vaccine: Hope or Premature Hype?” 18/09/2025
  • The Sudden Deaths and COVID Vaccines: A Critical Analysis of the ICMR and AIIMS Studies 17/09/2025
  • KGMU Scandal: Dr. Tulika Chandra Exposed in Crore Rupee Forgery and Scam 16/09/2025
  • Zydus to launch market-specific dosage variants of Semaglutide, MD says 15/09/2025
  • Biocon Biologics Launches Nepexto, Etanercept Biosimilar in Australia 15/09/2025
  • India launched its first National Biofoundry Network 15/09/2025
  • India has 94 Biotech Incubators across 25 states over 13 years 15/09/2025
Archives
Categories
  • Articles
  • Biotech News
  • Controversial
  • Editorials
  • Events
  • Featured
  • Guest Articles
  • Interviews
  • Interviews – Academia
  • Interviews – Industry
  • News-Industry
  • News-Research
  • Policies
  • SARS- CoV2 & COVID-19 Updates
  • Start-ups
About Us

About Biotech Express

Advisory and Editorial Board

Contact Us

Submission Policy and Guidelines

Submission policies

 

 

Follow us on Social Media
  • Facebook
  • Twitter
  • YouTube
We use cookies to help provide and enhance our service and tailor content and ads. By continuing you agree to the use of cookies. Copyright © 2013-2025 Biotech Express except certain content provided by third parties.

Type above and press Enter to search. Press Esc to cancel.